Immune-checkpoint inhibitors in pituitary malignancies

none8noTo date, there are no standardized systemic treatment options for patients with metastatic pituitary carcinoma progressed to chemo and radiation therapy. Immune-checkpoint inhibitors (ICIs) have been successfully assessed in other solid malignancies and could be a concrete hope for these patients. We performed a critical review of the literature aimed to evaluate studies assessing ICIs in pituitary malignancies. We also conducted research about published translational data assessing immune-contexture in these malignancies. Some preliminary reports reported a successful administration of pembrolizumab or the combination between nivolumab and ipilimumab in patients with metastatic ACTH-secreting pituitary carcinomas. Translational data suggest that adenomas secreting growth hormone and ACTH have a suppressed immune-microenvironment, which could be more likely to benefit from ICIs. Immune-checkpoint inhibitors can be an effective treatment in patients with pituitary carcinoma and maybe also recurrent adenoma. Tumors secreting growth hormone and ACTH are more likely to benefit from ICIs due to a different immune-microenvironment.mixedDi Nunno Vincenzo;Franceschi Enrico;Tosoni Alicia; Gatto Lidia;Maggio Ilaria;Lodi Raffaele; Bartolini Stefania; Brandes Alba ADi Nunno Vincenzo;Franceschi Enrico;Tosoni Alicia; Gatto Lidia;Maggio Ilaria;Lodi Raffaele; Bartolini Stefania; Brandes Alba